Abstract
Despite the discovery of anti-endothelial cell antibodies (AECA) in a heterogeneous group of disorders characterized by endothelial damage, their pathogenic role is still debated. Experimental in vitro models indicate that they can either damage endothelial cells or trigger cell signaling by reacting with as yet undefined surface molecules. However, clinical studies suggest that, in addition to AECA, other pathogenic mechanisms are involved in the vasculitic process. Recently, antibodies specific for β2 glycoprotein I, the phospholipid-binding protein targeted by anti-phospholipid antibodies, have been shown to display anti-endothelial activity. These autoantibodies recognize β2 glycoprotein I adhered to the endothelium and induce a cell perturbation that might underlie the thrombophilic state of the antiphospholipid syndrome.
| Original language | English |
|---|---|
| Pages (from-to) | 275-281 |
| Number of pages | 7 |
| Journal | Trends in Immunology |
| Volume | 26 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - May 2005 |
Fingerprint
ASJC Scopus subject areas
- Immunology
- Immunology and Allergy
Cite this
Humoral autoimmunity against endothelium : Theory or reality? / Meroni, Pierluigi; Ronda, Nicoletta; Raschi, Elena; Borghi, Maria O.
In: Trends in Immunology, Vol. 26, No. 5, 05.2005, p. 275-281.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Humoral autoimmunity against endothelium
T2 - Theory or reality?
AU - Meroni, Pierluigi
AU - Ronda, Nicoletta
AU - Raschi, Elena
AU - Borghi, Maria O.
PY - 2005/5
Y1 - 2005/5
N2 - Despite the discovery of anti-endothelial cell antibodies (AECA) in a heterogeneous group of disorders characterized by endothelial damage, their pathogenic role is still debated. Experimental in vitro models indicate that they can either damage endothelial cells or trigger cell signaling by reacting with as yet undefined surface molecules. However, clinical studies suggest that, in addition to AECA, other pathogenic mechanisms are involved in the vasculitic process. Recently, antibodies specific for β2 glycoprotein I, the phospholipid-binding protein targeted by anti-phospholipid antibodies, have been shown to display anti-endothelial activity. These autoantibodies recognize β2 glycoprotein I adhered to the endothelium and induce a cell perturbation that might underlie the thrombophilic state of the antiphospholipid syndrome.
AB - Despite the discovery of anti-endothelial cell antibodies (AECA) in a heterogeneous group of disorders characterized by endothelial damage, their pathogenic role is still debated. Experimental in vitro models indicate that they can either damage endothelial cells or trigger cell signaling by reacting with as yet undefined surface molecules. However, clinical studies suggest that, in addition to AECA, other pathogenic mechanisms are involved in the vasculitic process. Recently, antibodies specific for β2 glycoprotein I, the phospholipid-binding protein targeted by anti-phospholipid antibodies, have been shown to display anti-endothelial activity. These autoantibodies recognize β2 glycoprotein I adhered to the endothelium and induce a cell perturbation that might underlie the thrombophilic state of the antiphospholipid syndrome.
UR - http://www.scopus.com/inward/record.url?scp=27144485326&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27144485326&partnerID=8YFLogxK
U2 - 10.1016/j.it.2005.03.006
DO - 10.1016/j.it.2005.03.006
M3 - Article
C2 - 15866241
AN - SCOPUS:27144485326
VL - 26
SP - 275
EP - 281
JO - Trends in Immunology
JF - Trends in Immunology
SN - 1471-4906
IS - 5
ER -